The Development of Endoxifen for Breast Cancer
- 1 February 2018
- editorial
- Vol. 16 (2), 102-105
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 2017
- Adjuvant Ovarian Suppression in Premenopausal Breast CancerThe New England Journal of Medicine, 2015
- Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypesBritish Journal of Pharmacology, 2014
- Pharmacological Relevance of Endoxifen in a Laboratory Simulation of Breast Cancer in Postmenopausal PatientsJNCI Journal of the National Cancer Institute, 2014
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast CancerThe New England Journal of Medicine, 2014
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8Clinical Cancer Research, 2013
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With TamoxifenJAMA, 2009
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer CellsCancer Research, 2009
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI Journal of the National Cancer Institute, 2003